2.40

2.44% -0.06

Organogenesis Holdings Inc (ORGO)

Overview News Price History Option Chain Financials Discussions Forecast

Organogenesis Holdings Inc stock is traded at $2.40, with a volume of 1.34M. It is down -2.44% in the last 24 hours and down -2.83% over the past month. Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.

Previous Close:

$2.46

Open:

$2.47

24h Volume:

1.34M

Relative Volume:

0.93

Market Cap:

$308.82M

Revenue:

$514.70M

Net Income/Loss:

$2.72M

P/E Ratio:

-15.10

EPS:

-0.1589

Net Cash Flow:

$17.08M

1W Performance:

+1.69%

1M Performance:

-2.83%

6M Performance:

-42.99%

1Y Performance:

-45.45%

1-Day Range:

$2.36

$2.47

1-Week Range:

$2.345

$2.59

52-Week Range:

$2.04

$7.0771

Organogenesis Holdings Inc Stock (ORGO) Company Profile

Name

Organogenesis Holdings Inc

Sector

Healthcare (1096)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

781-575-0775

Address

85 DAN ROAD, CANTON, MA

Employee

854

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

ORGO's Discussions on Twitter

Compare ORGO vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ORGO Organogenesis Holdings Inc	2.40	308.82M	514.70M	2.72M	17.08M	-0.1589
TAK Takeda Pharmaceutical Co Adr	16.56	52.88B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.76	42.98B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	32.95	38.37B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	75.56	31.68B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	547.06	23.22B	3.17B	1.29B	1.01B	27.09

Organogenesis Holdings Inc Stock (ORGO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-28-24	Initiated	Lake Street	Buy
Feb-07-24	Initiated	Cantor Fitzgerald	Overweight
Jun-15-23	Initiated	Morgan Stanley	Equal-Weight
May-24-23	Upgrade	BTIG Research	Neutral → Buy
Nov-10-22	Downgrade	BTIG Research	Buy → Neutral
Aug-10-22	Downgrade	Oppenheimer	Outperform → Perform
Jan-10-20	Initiated	SVB Leerink	Outperform
Aug-26-19	Resumed	Credit Suisse	Outperform
May-02-19	Initiated	Credit Suisse	Outperform
Apr-17-19	Initiated	Oppenheimer	Outperform
Apr-11-19	Initiated	SunTrust	Buy

View All

Organogenesis Holdings Inc Stock (ORGO) Latest News

Jul 10, 2026

Organogenesis Holdings outlines regenerative medicine path as investors weigh long-term growth - ad-hoc-news.de

Jul 07, 2026

Organogenesis Amnuvx Gets FDA Review for Knee OA - AllSci

Jul 07, 2026

Jul 06, 2026

FDA accepts Organogenesis’ application for knee osteoarthritis treatment - Investing.com

Jul 06, 2026

Organogenesis' Biologics License Application for ReNu Accepted by FDA for Review - Moomoo

Jul 06, 2026

FDA accepts Organogenesis' Biologics License Ap... - Pluang

Jul 06, 2026

Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis - The Manila Times

Jul 06, 2026

Organogenesis wins FDA review for ReNu, a knee osteoarthritis treatment - Stock Titan

Jul 06, 2026

Jul 05, 2026

ORGO Q1 2026 Earnings: EPS Misses Estimates Amidst Operational ChallengesCFO Commentary Report - dars.gov.et

Jul 05, 2026

Jul 02, 2026

ORGO Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Stock DeclinesUpward Estimate Revision - dars.gov.et

Jul 02, 2026

Enterprise value to revenue forward of Organogenesis Holdings Inc. – NASDAQ:ORGO - TradingView

Jul 02, 2026

Jul 01, 2026

Price to book forward of Organogenesis Holdings Inc. – NASDAQ:ORGO - TradingView

Jul 01, 2026

Price to sales forward of Organogenesis Holdings Inc. – NASDAQ:ORGO - TradingView

Jul 01, 2026

Organogenesis | 10-K: FY2025 Annual Report - Moomoo

Jul 01, 2026

Jun 30, 2026

Enterprise value to EBITDA forward of Organogenesis Holdings Inc. – NASDAQ:ORGO - TradingView

Jun 30, 2026

Jun 29, 2026

Price to earnings forward of Organogenesis Holdings Inc. – NASDAQ:ORGO - TradingView

Jun 29, 2026

Organogenesis Holdings Inc.(NasdaqCM:ORGO) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026

Price to earnings forward of Organogenesis Holdings, Inc. Class A – LSX:A2PA31 - TradingView

Jun 29, 2026

Organogenesis Holdings Inc.(NasdaqCM:ORGO) dropped from Russell 2500 Growth Benchmark - marketscreener.com

Jun 29, 2026

Organogenesis Holdings Inc.(NasdaqCM: ORGO) added to Russell 2000 Value Benchmark - marketscreener.com

Jun 29, 2026

Organogenesis Holdings Inc.(NasdaqCM:ORGO) added to Russell Microcap Value Benchmark Index - marketscreener.com

Jun 29, 2026

Enterprise value to EBIT forward of Organogenesis Holdings, Inc. Class A – LSX:A2PA31 - TradingView

Jun 29, 2026

Organogenesis Holdings Inc.(NasdaqCM:ORGO) dropped from Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026

Organogenesis Holdings Inc.(NasdaqCM:ORGO) dropped from Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Organogenesis Holdings Inc.(NasdaqCM:ORGO) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com

Jun 28, 2026

Organogenesis Holdings Inc.(NasdaqCM:ORGO) added to Russell Small Cap Comp Value Benchmark - marketscreener.com

Jun 28, 2026

Jun 26, 2026

Organogenesis Holdings, Inc. Class A Actuals & Estimates (NASDAQ:ORGO) - TradingView

Jun 26, 2026

Jun 25, 2026

ORGO Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026